Thrombosis in the context of pediatric cardiac surgery is usually considered a clinically important but somewhat rare complication. Thus, awareness has been limited, likely resulting in a failure to identify this potentially important clinical problem, reporting biases, inappropriate/insufficient use of diagnostic tests, and a lack of prospective clinical studies. This topic has not been a major research focus in the past. In a review of 1542 pediatric cardiac surgeries, we found that 171 (11%) were associated with incident thrombosis, with multiple subpopulations at substantially higher risk. There were no systematic detection protocols in place during the study period; thus, it is very likely that our estimated thrombosis prevalence of 11% is an underestimation and that this is a much more prevalent problem than reported here. Thrombosis was associated with a high degree of serious complications (28%), with increased morbidity and worse postoperative clinical outcomes compared with surgeries without thrombosis. Both thrombus and patients' characteristics were associated with increased odds of serious complications and thrombus resolution, and these factors could be used for future risk stratification. Further research is necessary to determine the mechanisms by which the identified factors are associated with thrombosis and its outcomes by focusing on pathways of coagulation and platelet activation. This study establishes thrombosis in the context of pediatric cardiac surgery as an important clinical problem and will, we hope, form the basis of further research aimed at better prevention, detection, and treatment of those complications. See p 1511.
Impact of Exercise on Heart Rate Recovery
An abnormal heart rate recovery has been shown to have prognostic value in multiple patient populations and to give additional prognostic information independently of functional capacity, ischemia, or coronary artery disease. However, whether abnormal heart rate recovery can be reversed is controversial. Because exercise has been shown to improve autonomic tone, it stands to reason that perhaps exercise training can improve abnormal heart rate recovery. To date, studies of cardiac rehabilitation on heart rate recovery have been limited by small sample size. In our study of 1070 consecutive patients who underwent symptom-limited exercise ECG testing before and after completion of phase 2 cardiac rehabilitation, we found that heart rate recovery improved with exercise training. There was a strong association of abnormal heart rate recovery at exit of cardiac rehabilitation with all-cause mortality. Patients who had abnormal heart rate recovery at baseline but had normalized heart rate recovery at exit had survival rates similar to those with normal heart rate recovery. The beneficial autonomic effect of exercise training, specifically enhanced vagal reactivation, suggests a plausible explanation as to why exercise training may favorably improve heart rate recovery. See p 1520.
Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)
The Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial showed that cardiac resynchronization-defibrillator therapy is associated with a significant reduction in the risk of heart failure or death compared with defibrillator-only therapy. Currently, however, there is limited information on the factors that can be used to distinguish between responders and nonresponders in this population. In the present study, we developed a response score that was based on 7 factors we identified as being associated with favorable reverse remodeling in MADIT-CRT: female sex, a nonischemic origin of cardiomyopathy, left bundle-branch block, QRS Ն150 milliseconds, prior hospitalization for heart failure, left ventricular end-diastolic volume Ն125 mL/m 2 , and left atrial volume Ͻ40 mL/m 2 . The score was then used to assess the clinical benefit of cardiac resynchronization-defibrillator therapy during the trial. We show a direct correlation between an increasing response score and the magnitude of the reduction in the risk of heart failure or death with cardiac resynchronization therapy. There was a significant 13% increase in the clinical benefit of cardiac resynchronizationdefibrillator therapy per 1-point increment in the response score and a significant direct correlation between risk reduction associated with cardiac resynchronization-defibrillator therapy and response score quartiles. Thus, our findings suggest that combined assessment of factors associated with reverse remodeling can be used for improved selection of patients for cardiac resynchronization therapy. See p 1527.
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Chronic and acute stress to the heart results in a pathological remodeling response accompanied by cardiomyocyte hypertrophy, fibrosis, pump failure, myocyte degeneration, and apoptosis, which often culminate in heart failure and sudden death. Although classic pharmacological treatment strategies can reduce remodeling and prolong survival in heart failure patients, these therapies are ultimately ineffective in preventing progression of the disease. Previously, we identified a microRNA, miR-208, encoded within an intron of the Myh6 gene that regulates the cardiac stress response. Although genetic deletion of miR-208 in mice failed to induce an overt phenotype at baseline, in response to several forms of cardiac stress, miR-208 -null mice showed virtually no cardiomyocyte hypertrophy or fibrosis and were unable to upregulate Myh7 expression. Data presented in this study show that delivery of a locked nucleic acid-modified anti-miR against miR-208a in mice induces highly specific and sustained silencing of miR-208a in the heart without any observable side effects. Therapeutic silencing of miR208a via subcutaneous delivery of antimiR-208a prevents pathological cardiac remodeling, functional deterioration, and lethality during heart disease. These beneficial effects correspond to significant changes in miRNAs within plasma. Our data show the potent beneficial effects of miR-208a inhibition, which could be very relevant for patients suffering from heart failure. Because miR-208a is the sole cardiac-specific miRNA annotated so far, we believe that antimiR-208a might become a combination therapy with the current standard of care. See p 1537.
Acute Hypoglycemia Decreases Myocardial Blood Flow Reserve in Patients With Type 1 Diabetes Mellitus and in Healthy Humans
Hypoglycemia is a common problem that occurs in almost 20% of patients receiving intensive insulin therapy in hospital. Several
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Original Research Put Into Perspective for the Practicing Clinician Volume 124 Ⅲ Number 14 Ⅲ October 4, 2011 studies have recently shown that hypoglycemia is associated with an increase in cardiovascular mortality. This association has been demonstrated in people with and without established coronary artery disease. Importantly, patients with acute coronary syndromes appear to have worse short-and long-term outcomes if they experience hypoglycemia in the acute phase of their presentation. The pathophysiological mechanism responsible for this association is not known. This present study examined the effects of hypoglycemia on myocardial blood flow (MBF) reserve using myocardial contrast echocardiography in subjects with type 1 diabetes mellitus and healthy control subjects. With the use of a 1-step hyperinsulinemic clamp technique, insulin-induced hypoglycemia decreased the MBF reserve in both patients with type 1 diabetes mellitus and healthy subjects. Furthermore, during hyperinsulinemic euglycemia, insulin induced a marked increase in peak MBF and MBF reserve, whereas hypoglycemia led to an increase in resting MBF and a decrease in peak MBF, thereby decreasing the MBF reserve overall. This effect was observed in both healthy individuals and patients with type 1 diabetes mellitus. We speculate from our results that alterations in MBF reserve may provide an explanation for the observed association between hypoglycemia and increased cardiovascular mortality in susceptible individuals. See p 1548.
Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention
Drug-eluting stents for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting drug-eluting stent use in patients at the highest risk for target vessel revascularization, we developed and validated a model to predict target vessel revascularization from a contemporary population-based registry in Massachusetts based on commonly collected clinical and angiographic variables that are obtainable before percutaneous coronary intervention. The ability of the model to discriminate 1-year target vessel revascularization risk among percutaneous coronary intervention patients was significantly better than a simpler model based on the presence of diabetes mellitus, stent length, and stent diameter (c statistic, 0.66 versus 0.60; integrated discrimination index, 0.013; PϽ0.001). The predicted reduction in target vessel revascularization associated with drug-eluting stents use ranged from as little as 1.2% (95% confidence interval, 0.9 -1.6) to 15.9% (95% confidence interval, 13.0 -18.4), depending on patient characteristics. Because the predicted benefit associated with drug-eluting stents varies broadly among patients, this predictive model may be used to support the optimal use of drug-eluting stents in a prospective fashion and to engage patients in the decision-making process before coronary intervention. See p 1557.
Arterial Pulse Wave Dynamics After Percutaneous Aortic Valve Replacement: Fall in Coronary Diastolic Suction With Increasing Heart Rate as a Basis for Angina Symptoms in Aortic Stenosis
Using the new technique of percutaneous aortic valve replacement in combination with wave intensity analysis, we have identified abnormalities in coronary physiology that are rapidly restored to normal after valve implantation. In addition to being of mechanistic interest, quantification of coronary physiological reserve and in particular its paradoxical reversal may offer a potential way of assessing the severity of aortic stenosis in the presence of comorbidities that may mimic or obscure anginal symptoms. Although currently it is possible to do this analysis only with offline analysis tools, the computational processing requirements are minimal and easily automatable, making online analysis a realistic vision for the future. See p 1565.
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Dabigatran and rivaroxaban are new oral anticoagulants that have been evaluated for the prevention and treatment of arterial and venous thrombosis and have subsequently been licensed in the United States, Canada, and Europe for various indications. Both drugs have stable pharmacodynamic profiles, obviating repeated laboratory control and dose adjustments, thereby making them an attractive replacement for vitamin K antagonists such as warfarin. A big disadvantage of these new anticoagulant agents is the lack of a method of reversal in case of major hemorrhage or the need to perform emergency invasive procedures. In the present study, for the first time, the effect of prothrombin complex concentrate was assessed in healthy volunteers who were anticoagulated with either drug. Results from this study show that prothrombin complex concentrate completely and directly reversed the effect of rivaroxaban on the coagulation system, whereas the effect of dabigatran was unaffected. We believe these results are highly relevant for a broad audience such as cardiologists, physicians, and other specialists treating patients with anticoagulant agents. With both drugs on the market, the risk of severe bleeding complications or the need for reversal in case of emergency surgery is clearly present, and the results from this study, when confirmed in the clinical situation, may serve to guide management for these patients. See p 1573.
